We represented Abcam, a Cambridge, UK public company, in its acquisition of MitoSciences Inc., an Oregon-based leading developer of mitochondrial antibodies and mitochondrial assays. We acted as lead counsel for the acquiror in structuring and executing the deal, a reverse subsidiary merger in which the consideration consisted of cash and stock in the acquiror.